You are on page 1of 5

Institutional Equity Research

Jyothy Laboratories Ltd
September 17, 2013

Management Meet Note
Current price Target price Upside/(downside) Earning estimate Rs Rs %

154 178 16 Revised

Competition becomes aggressive in detergents
From our recent interaction with the management we gathered that a) the competition in detergents segment is getting tougher as HUL has introduced many promotional offers to squeeze out the smaller players b) input cost table has moved unfavourably for JLL due to 20% rise in crude oil prices and due to weakening rupee leading to erosion of 200bps at gross margin level. Heavy promotions in detergents leads to price deflation; top line growth in FMCG business to be at 25% in F14: We believe that HUL has introduced heavy promotional offers on its flagship detergent powder Surf offering Rin bar worth Rs10 free leading to price deflation in the category which had already seen pricing anniversary effect in 1QF14. Raw materials like LAB (up 6% YTD) and soda ash (up 16% YTD) are causing pressure on margin for the industry and more so on smaller players like JLL, Ghari or Nirma than the larger players like HUL or P&G as they have deep pockets. Detergents contribute to 25% (SSLe) to the top line for JLL and we believe that the growth will be muted in that category for JLL. However, we believe that due to repackaging in Ujala Supreme and new marketing campaigns in Margo, Pril, Fa, Mr. White and Maxo will hold up the sales. EBITDA estimates cut by 20% to account for input cost pressure and higher ad-spends: We are trimming the gross margin estimate for F14 from 49% to 47% as a) we reduced the gross margin for FMCG business (JLL standalone excl. laundry services) from 48% to 46% to account for 200bps erosion due to increase in input costs like LAB, soda ash and crude oil by 6%,16% and 20% YTD resp. b) we have increased ad-spends costs to Rs1.52bn (11.5% of sales) from Rs1.27bn (up 20%) as they spent Rs390mn in 1QF14 of which Rs270mn was regular TV ads (up by 22%) and the rest was one-time costs of new creative for Margo, Pril and Fa. In 3QF14, JLL is launching a revolutionary product in HI segment under Maxo which we believe will entail high marketing expenses.

Market data Mkt capitalisation Average daily vol 52-week H/L Shares O/S Free float Promotor holding Foreign holding Face value

Rs bn '000 Rs mn mn % % Rs

25.5 110.7 211 / 139 166.0 60.3 63.7 17.0 1.0

Price performance (%) Nifty (abs) Stock (abs) Relative to Index 1m 5.8 (6.4) (12.3) 3m (0.4) (19.2) (18.8) 6m (0.7) (7.6) (6.9) 1yr 3.9 (3.3) (7.2)

Performance 220 (Rs)
200 180 160 140






Sep-12 Dec-12 Mar-13 Jun-13 Sep-13 Jyothy Laboratories Rel. to BSETMCG

Source: Bloomberg, SSL

Financial summary
Y/E March (Rs mn) Sales Growth(%) EBIDTA margin (%) Net Profit Adj. net profit NPM(%) Growth(%) EPS - Reported (Rs) EPS - Core (Rs) P/E (x) Dividend yield (%) RoCE(%)
Sagarika Mukherjee +91 22 4227 3386

F 12 9,130 45.5 9.2 446 446 4.9 (35.2) 2.8 2.8 55.7 1.6 12.2 6.2

F 13 11,060 21.1 11.7 196 478 4.3 7.1 1.2 3.0 126.4 1.6 24.8 2.5

F 14e 13,243 19.7 12.0 757 757 5.7 58.6 4.6 4.6 33.8 1.6 34.4 10.9

F 15e 16,503 24.6 13.0 1,376 1,376 8.3 81.8 8.3 8.3 18.6 1.6 44.9 17.7

RoE(%) Source: Company, SSLe

SBICAP Research on Bloomberg SBICAP <GO>,

Please refer to our disclaimer given at the last page.

Outlook and Valuation: Based on the run-rate observed in June in which the full effect of new brand communications were evident.8/10. Accordingly we arrive at an EPS estimate of Rs4. sagarika. we believe that the strong gross margin expansion trend will be only a 1HF14 phenomenon.3.6/8. 2013 | 2 .com September 17. The improvement came about as JLL had rationalised the trade margins by 4% for most of the products and reduced warehouses from 64 to 30 over last one year. the stock is trading at 34x/19x our EPS estimate of Rs4.mukherjee@sbicapsec. However.2% was led by 686bps improvement in gross margin. At CMP of Rs154.Jyothy Laboratories Ltd . we have trimmed our EPS estimates down by 34% for F14 as a) we have reduced gross margin estimate for F14 49% to 47% b) increased ad-spends by 20% for the several product launches.5x F15e earnings estimate of Rs8. we have maintained our estimate for top line growth of 25% in F14 and F15.Competition becomes aggressive in detergents SBICAP Securities Ltd Cut in trade margin benefit will be in base by 3QF14: In 1QF14.3 earlier.3 for F14/F15 from Rs6. JLL reported an increase in EBITDA margin by 366bps to 15. We reduce our TP by 15% from Rs210 to Rs178 valuing it at 21.6/8. As this change was implemented fully by 3QF13.3 in –line with sector valuations.

mukherjee@sbicapsec.316 904 1.0 47.8 2.6 8.910 11.0 8.9 52.423 458 3.5 1.1 1.1 14.3 1.4 429.136.561 6.592 12.5 1.Core (Rs) 9.7 18.6 1.448 31 5.4 246.349 (666) (7.094 663 September 17.RoE NPM(%) Leverage Asset turnover RoE(%) 4.7 58.8 1.4 1.683 49 4.7 35.693) 611 # Balance sheet Y/E March (Rs mn) Share Capital Reserves Total shareholder's Equity Minority interests Debt Deferred tax liability Total liabilities Tangible assets Intangible assets Fixed assets Investments Current Assets Inventories Receivables Loans & advances Cash Current Liabilities Payables Provisions Deferred tax asset Total Assets Source: SSLe Key ratios Y/E March F12 81 6.628 10.107) F13 196 224 682 (52) 145 (268) 631 204 (535) (3) 52 (5) (287) (682) (403) (107) 499 (694) (205) F14e 757 224 680 (52) 486 1.0 1.137 13.030 4.2 23.0 52.0 9.795 1.7 34.0 6.460 1.367.9 11.2 3.7) 590.2 1.8 8.6 0.8 sagarika.9 18. in goodwill Purchase of investments(net) Interest Received Others CFI Interest Paid Dividend Paid Proceeds from issue of shares Long term debt Debt to subsidiaries Inc.522 7.776) 271 F15e 1.220 6.7 47.4 695 7.685 2.165 13.6 0.609 (100) 52 (48) (680) (415) (1) (680) (1.2 1.391 869 2 11.366 34 3.8 11.185 (2.628 10.6 4.2 (148.3 583.3 227.1 1.5 52.060 21.366 2.5 199.297 11.528 11.Jyothy Laboratories Ltd .5 26.260 3.6 F15e 16.6 1.6 F13 161 6.0 34.5 739.856 9 11.304.8 F14e 34.8 955 8.344 869 11.2) 2.213 2.6 0.3 5.5 238.6 2.3 597.2 11.5 Du Pont Analysis .917 2.5 5.6 1.9 6.3 682.453 8.0 442.7 757 757 5.019 6.1 3.722 808 1.5 17.844 5.722 49 4.125 67 5.718 2. net profit NPM(%) Growth(%) EPS .2 4.341 4.0 20.616 12.0 739.4 11.2 20.2 224.376 1.100 45 1.8 196 478 4.7 7.6 0.8 29.503 24.044 6.8 107.3 224.130 45.7 1.4 107.0 146.3 1.4 8.636 F14e 161 7.7 446 446 4.3 1.3 7.905) (238) (403) 62 4.224 47 1.7 132.146 (100) 52 (48) (598) (415) (680) (1.2 3.643 161 11.828 370 11.068 967 903 730 3.6 8.3 680.9 1.8 224.8 F15e 44.1 61.488.763 1.0 146.5 F13 24.9 2.093) (574) 227 200 (7.5 26.0 F14e 13.4 24.2 52.5 12.7 2.697 31 4.289 841 9.093 10.050 49 1.8 2.7 11.698 2.Reported (Rs) EPS .659 15.3 43.0 34.6 4.837.953 (188) 4.4 28.5 0.9 33.975 F14e 161 6.9 100.381 49 5.996 F12 12.820 7.7 1.9 2.8 F13 11.536 9 11.6 14.198 1.7 47.636 2.3 384.243 19.6 1.3 81.5 3.069 7.216 47 1.1 1.5 5.0 2.376 8.8 1.0 22.273 7. in provisions CFF Net change in cash 446 247 238 (227) 265 700 1.0 146.945 7.816 869 1 11.628 10.6 5.4 1.176 9 11.9 35.975 3.2 32.Competition becomes aggressive in detergents SBICAP Securities Ltd Financials Income Statement (Y/E March ) Y/E March (Rs mn) F12 Total Revenues Growth rate (%) COGS Gross Profit Gross margin(%) Employee Costs Share of Net Sales(%) Ad-spends Share of Net Sales(%) Other manufacturing costs Share of Net Sales(%) Total expenses EBITDA EBITDA Margin(%) Growth rate(%) Depreciation Interest Expense Other income PBT Tax PAT Minority Interest Extraordinary items Net Profit Adj.427 15.6 17.6 12.652 1. 2013 | 3 .9 (35.088 1.996 3.1 5.572 31 4.3 8.2 0.917 RoCE(%) Inventory Days Receivables Days Loans and Advances Days Payable Days Provision Days Cash Conversion Cycle (Days) Valuation Ratios P/E (x) P/Sales(x) EV/EBITDA(x) P/BV(x) FCF yield (%) Dividend Yield(%) D/E(x) 55.7 54.367.2 86.376 224 598 (52) 206 2.188 807 1.4 19.3 # 0 # 0 0 # # 0 0 # 0 # 0 0 # # 0 # # 0 0 Cash Flow Statement (Y/E March) Y/E March (Rs mn) F12 Net Profit Depreciation/Amortisation Interest expense Interest income (Inc)/Dec in Wcap Others CFO Capex Inc.

believed to be reliable. by mere inclusion in this report. SSL will not treat recipients as clients by virtue of their receiving this report. It should not be construed as an offer to sell or solicitation of an offer to buy. traders and other professionals may provide oral or written market commentary or trading strategies to its clients that reflect opinion that are contrary to the opinions expressed herein. SSL’s sales people. or will be directly or indirectly related to the specific recommendations or views in this report. SBICAP (UK) Limited and SSL are collectively referred to as SBICAP Entities]. Joshi Marg. Recipients of this report should assume that SBICAP Entities (and/or its Affiliates) is seeking (or may seek or will seek) Investment Banking. Should not be regarded. 2013 | 4 . M. as a representation or warranty by or on behalf of SSL the authors of this report. Though disseminated to clients simultaneously. SBICAP (Singapore) Limited. This report does not solicit any action based on the material contained herein. 2=HOLD (expected to give absolute returns between -10 to 15 percentage points). Sagarika Mukherjee M. 289) of Singapore.f. fees or other compensation from the company or companies that are the subject of this material/ report. you should be aware that any or all of the foregoing. (Financial Economics) author of this report. including the analysts and others involved in the preparation/issuance of this material and their dependant(s).e.: 91-22-42273300/01 | Fax: 91-22-42273335 | Email: sbicapresearch@sbicapsec. 1=BUY (expected to give absolute returns of 15 or more percentage points). may give rise to potential conflicts of interest. that these or their underlying assumptions will be achieved. whatsoever. sagarika. SBICAP (Singapore) Limited’s services are available only to accredited investors (other than individuals). (NSE) and Bombay Stock Exchange Ltd. SBICAP (Singapore) Limited. a fellow subsidiary of SSL. may on the date of this report/from time to time. Mumbai -400013. act as principal in. SSL is a wholly owned subsidiary of SBI Capital Markets Limited (SBICAP). brokerage. is. BUY BUY BUY BUY REDUCE REDUCE Rec. 3. will not materialize or will vary significantly from actual results. 2. project finance or other businesses and may receive commission. and such variances may increase over time. SSL (and/or its Affiliates) and its officers. This report is for information purposes only and SBICAP Entities accept no liabilities for any loss or damage of any kind arising out of the use of this report. hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuers or securities. advisory. [SBICAP. SBICAP (UK) September 17. Are based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. SSL may have earlier issued or may issue in future reports on the companies covered herein with recommendations/ information inconsistent or different from those made in this report. and its proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. No independent accountants have expressed an opinion or any other form of assurance on these. or any other person. purchase or subscribe to any securities this report shall not form the basis of or be relied upon in connection with any contract or commitment. SBICAP Securities Limited (SSL). February 2013) Guide to the expected return over the next 12 | www. among other things. SBICAP (Singapore) is a wholly owned subsidiary of SBICAP. This report has been prepared based upon information available to the public and sources. (BSE).Jyothy Laboratories Ltd . a fellow subsidiary of SSL. N. directors and employees. 4. 2nd Floor. A-Wing. dealers. BUY BUY BUY BUY Rating based on Current Rating System (Feb'13) SBICAP Securities Limited Corporate Office: Mafatlal KEY TO INVESTMENT RATINGS (w. incorporated in Singapore is regulated by the Monetary Authority of Singapore as a holder of a capital markets services license and an exempt financial adviser in Singapore. not all clients may receive this report at the same time. We also certify that no part of our compensation was. Sc. incorporated in United Kingdom is authorised and regulated by the Financial Services Authority. Can be expected that some of the estimates on which these were based. Are not prepared with a view towards compliance with published guidelines or generally accepted accounting principles. 3=SELL (expected to give absolute returns less then 10 percentage points) DISCLAIMER I. and institutional investors in Singapore as defined in section 4A of the Securities and Futures Act (Cap.Competition becomes aggressive in detergents SBICAP Securities Ltd Recommendation History 250 210 170 (Rs) 130 90 50 Nov-12 Jan-13 Jun-12 Jun-13 Jul-12 May-12 May-13 Mar-13 Feb-13 Oct-12 Apr-12 Apr-13 Jul-13 Aug-13 Aug-12 Sep-12 Dec-12 Sep-13 BUY Stock Price HOLD SELL Target Price Date 29-May-12 10-Jul-12 25-Jul-12 05-Sep-12 02-Nov-12 07-Dec-12 Date 11-Feb-13 24-May-13 16-Aug-13 17-Sep-13 Stock Price 110 122 122 151 177 187 Stock Price 145 180 164 154 TP 152 150 150 175 175 175 TP 200 210 210 178 Rec. In reviewing this document. Tel.a full service Stock Broking Company and a member of National Stock Exchange of India Ltd. and buy or sell the securities or derivatives thereof of companies mentioned herein. Lower Parel. The projections and forecasts described in this report should be carefully evaluated as these 1. which is engaged into the investment banking activities and is registered with the Securities and Exchange Board of India as a “Category I” Merchant Banker.mukherjee@sbicapsec. have long/short positions in. Please ensure that you have read “Risk Disclosure Document for Capital Market and Derivatives Segments” as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market.sbicapsec.

2013 | 5 . United Kingdom or Singapore or by any Stock Exchange in India. options. The materials are exempt from the general restriction on the communication of invitations or inducements to enter into investment activity on the basis that they are only being made to Relevant Persons and have therefore not been approved by an authorised person as would otherwise be required by section 21 of the Financial Services and Markets Act 2000 (“FSMA”). believed to be reliable. incidental. United Kingdom or Singapore. officer. or in connection with this report. SSL has reviewed the report and. Further. employees. The countries in which the companies mentioned in this report are organized may have restrictions on investments. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. SSL does not provide tax advice to its clients and you should independently evaluate the suitability of this report and all investors are strongly advised to seek professional consultation regarding any potential investment. advisor or agent of it. The opinions expressed in this report are subject to change without notice and have no obligation to tell the clients when opinions or information in this report change. Neither SBICAP Entities nor its directors. agents or representatives shall be liable for any damages whether direct or indirect. This report or any portion hereof may not be printed. United Kingdom: “This marketing communication is being solely issued to and directed at persons (i) fall within one of the categories of “Investment Professionals” as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. in case of any commitment on behalf of State Bank of India or SBI Capital Markets Limited or any entity in the State Bank Group. expressed or implied.mukherjee@sbicapsec. This report does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced. sold or distributed without the written consent of SBICAP Entities. but regulatory compliance or other reasons may prevent it from doing so. and observe. Further. employee. Past performance is not a guide for future performance. This report has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. or affiliate of any such person or such persons as to the accuracy. The securities discussed in this report may not be suitable for all the investors. authenticity. voting rights or dealings in securities by nationals of other countries. unincorporated associations etc. (ii) fall within any of the categories of persons described in Article 49 of the Financial Promotion Order (“High net worth companies. transmitted or published by the recipient. 201026168R). value and income of the investments referred to in this report may fluctuate and investors may realize losses on any investments. and other derivatives as well as non-investment grade securities give rise to substantial risk and are not suitable for all investors. is made or given by or on behalf of SBICAP Entities. and persons into whose possession this document comes should inform themselves about.”) or (iii) any other person to whom it may otherwise lawfully be made available (together “Relevant Persons”) by SSL. No representation or warranty. a holder of a capital markets services license and an exempt financial adviser in Singapore and solely to persons who qualify as institutional investors or accredited investors (other than individuals) as defined in section 4A(1) of the Securities and Futures Act.Competition becomes aggressive in detergents SBICAP Securities Ltd It does not constitute a personal recommendation and does not take into account the specific investment September 17. nor any person who controls it or any director. any liability or responsibility is expressly disclaimed. any such restrictions. such commitment is valid only when separately confirmed by that entity. SSL endeavors to update on a reasonable basis the information discussed in this document/material/ report. the current or historical information included here is believed to be reliable. the accuracy and completeness of which is not guaranteed. as amended (the “Financial Promotion Order”). Certain transactions including those involving futures. This report may not be all inclusive and may not contain all the information that the recipient may consider material. special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. completeness or fairness of the information or opinions contained in this report and SBICAP Entities or such persons do not accept any responsibility or liability for any such information or opinions and therefore. Legal Entity Disclosure Singapore: This report may be distributed in Singapore by SBICAP (Singapore) Limited (Registration No. accounting or tax advice. The report is for the use and consumption of the recipient only. This report/document has been prepared by SSL based upon information available to the public and sources.Jyothy Laboratories Ltd . The price. Investors in securities such as ADRs. Persons in Singapore should contact SBICAP (Singapore) Limited in respect of any matters arising from. sagarika. express or implied is made that it is accurate or complete. no representation or warranty. Distributing /taking/sending/dispatching/transmitting this document in certain foreign jurisdictions may be restricted by law. Actual results may differ materially from those set forth in projections. Chapter 289 of Singapore (the “SFA”) and is not intended to be distributed directly or indirectly to any other class of person. Failure to comply with this restriction may constitute a violation of any foreign jurisdiction laws. financial situation/circumstances and the particular needs of any specific person who may receive this document. Nothing in this report is intended by SBICAP Entities to be construed as legal.” This report is issued and distributed by SBICAP Entities without any liability / undertaking / commitment on the part of itselves or SBI Capital Markets Limited or State Bank of India or any other entity in the State Bank Group. the value of which are influenced by foreign currencies effectively assume currency risk.